156 related articles for article (PubMed ID: 20947470)
1. In vitro chemosensitivity of head and neck cancer cell lines.
Schuler PJ; Trellakis S; Greve J; Bas M; Bergmann C; Bölke E; Lehnerdt G; Mattheis S; Albers AE; Brandau S; Lang S; Whiteside TL; Bier H; Hoffmann TK
Eur J Med Res; 2010 Aug; 15(8):337-44. PubMed ID: 20947470
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.
Theile D; Gal Z; Warta R; Rigalli JP; Lahrmann B; Grabe N; Herold-Mende C; Dyckhoff G; Weiss J
Cancer Biol Ther; 2014 Apr; 15(4):436-42. PubMed ID: 24448417
[TBL] [Abstract][Full Text] [Related]
3. Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.
Syed N; Chavan S; Sahasrabuddhe NA; Renuse S; Sathe G; Nanjappa V; Radhakrishnan A; Raja R; Pinto SM; Srinivasan A; Prasad TS; Srikumar K; Gowda H; Santosh V; Sidransky D; Califano JA; Pandey A; Chatterjee A
Proteomics; 2015 Jan; 15(2-3):383-93. PubMed ID: 25327479
[TBL] [Abstract][Full Text] [Related]
4. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
[TBL] [Abstract][Full Text] [Related]
6. Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro.
Rigalli JP; Reuter T; Herold-Mende C; Dyckhoff G; Haefeli WE; Weiss J; Theile D
Cancer Chemother Pharmacol; 2013 May; 71(5):1335-43. PubMed ID: 23479137
[TBL] [Abstract][Full Text] [Related]
7. Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines.
Sakakibara A; Tsukuda M; Kondo N; Ishiguro Y; Kimura M; Fujita K; Takahashi H; Matsuda H
Auris Nasus Larynx; 2011 Oct; 38(5):589-99. PubMed ID: 21362583
[TBL] [Abstract][Full Text] [Related]
8. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
[TBL] [Abstract][Full Text] [Related]
9. Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Roy S; Roy S; Kar M; Padhi S; Saha A; Anuja K; Banerjee B
J Oral Pathol Med; 2018 May; 47(5):492-501. PubMed ID: 29575240
[TBL] [Abstract][Full Text] [Related]
10. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
11. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
[TBL] [Abstract][Full Text] [Related]
12. Cellular pharmacokinetic/pharmacodynamic relationship of platinum cytostatics in head and neck squamous cell carcinoma evaluated by liquid chromatography coupled to tandem mass spectrometry.
Theile D; Detering JC; Herold-Mende C; Dyckhoff G; Haefeli WE; Weiss J; Burhenne J
J Pharmacol Exp Ther; 2012 Apr; 341(1):51-8. PubMed ID: 22207655
[TBL] [Abstract][Full Text] [Related]
13. Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers.
Li F; Shanmugam MK; Siveen KS; Wang F; Ong TH; Loo SY; Swamy MM; Mandal S; Kumar AP; Goh BC; Kundu T; Ahn KS; Wang LZ; Hui KM; Sethi G
Oncotarget; 2015 Mar; 6(7):5147-63. PubMed ID: 25762616
[TBL] [Abstract][Full Text] [Related]
14. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
Xiao Y; Li JD; Shi HL; Liu JH; Feng YL; Li MD
Ai Zheng; 2007 Apr; 26(4):386-9. PubMed ID: 17430657
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin-mediated inhibition of survivin increases sensitivity of head and neck squamous cell carcinoma cell lines to paclitaxel.
Khan Z; Khan N; Varma AK; Tiwari RP; Mouhamad S; Prasad GB; Bisen P
Curr Cancer Drug Targets; 2010 Nov; 10(7):660-9. PubMed ID: 20578991
[TBL] [Abstract][Full Text] [Related]
16. Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel.
Ley J; Wildes TM; Daly K; Oppelt P; Adkins D
Med Oncol; 2017 Feb; 34(2):28. PubMed ID: 28078561
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma.
Theile D; Ketabi-Kiyanvash N; Herold-Mende C; Dyckhoff G; Efferth T; Bertholet V; Haefeli WE; Weiss J
Head Neck; 2011 Jul; 33(7):959-68. PubMed ID: 20737486
[TBL] [Abstract][Full Text] [Related]
18. The synergistic cytotoxicity of cisplatin and taxol in killing oral squamous cell carcinoma.
Huang GC; Liu SY; Lin MH; Kuo YY; Liu YC
Jpn J Clin Oncol; 2004 Sep; 34(9):499-504. PubMed ID: 15466821
[TBL] [Abstract][Full Text] [Related]
19. Hyperphosphorylation of replication protein A in cisplatin-resistant and -sensitive head and neck squamous cell carcinoma cell lines.
Manthey KC; Glanzer JG; Dimitrova DD; Oakley GG
Head Neck; 2010 May; 32(5):636-45. PubMed ID: 19787780
[TBL] [Abstract][Full Text] [Related]
20. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of fusaric acid and paclitaxel or carboplatin.
Jaglowski JR; Stack BC
Cancer Lett; 2006 Nov; 243(1):58-63. PubMed ID: 16412572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
